Hoofa, on what basis are you saying it is seriously undervalued?
If you assume $1.2m EBITDA for FY18 as guided and then add back the R&D spend of $1.0m (which you could argue, given many companies would capitalise it and also the R&D tax incentive will likely be claimed and add back to cash income), or $2.2m EBITDA adjusted for R&D, then it's trading on approx ~7.0x EV/EBITDA on my calcs.
What do you think it should trade on? Maybe 10.0x plus for rapid growth?
Also, I would guess acquisition is part of the plan, so what can you buy a profitable ERP services business for? 4.0x to 5.0x I guess?
With $3.5m cash and trading on a high multiple, I would like to see them announce an acquisition to add to the organic growth so they can be re-rated to a high growth multiple of over 10.0x EV/EBITDA.
With the right deal adding $6m revenue and say $1.0m EBITDA (giving annualised $20m revenue and $3.2m adjusted for R&D), you could justify a valuation of 10.0 cents FY18
Interested in your thoughts.
- Forums
- ASX - By Stock
- JCS
- JCurve Solutions (JCS) - Oracle
JCurve Solutions (JCS) - Oracle, page-3
-
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add JCS (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
-0.003(12.0%) |
Mkt cap ! $7.223M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.2¢ | $3.359K | 152.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1178898 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 1233502 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1178898 | 0.020 |
1 | 200000 | 0.015 |
1 | 1000000 | 0.010 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 1233502 | 2 |
0.025 | 611346 | 1 |
0.027 | 492678 | 1 |
0.028 | 16000 | 1 |
0.029 | 385536 | 1 |
Last trade - 15.45pm 02/08/2024 (20 minute delay) ? |
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
JCS (ASX) Chart |